VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research report sent to investors on Monday,Benzinga reports. The firm currently has a $5.75 price target on the stock.

Separately, BTIG Research assumed coverage on VYNE Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $8.00 target price on the stock.

VYNE Therapeutics Price Performance

Shares of NASDAQ:VYNE opened at $3.92 on Monday. The stock’s 50-day moving average is $2.95 and its 200 day moving average is $2.31. The company has a market cap of $57.82 million, a PE ratio of -4.56 and a beta of 1.30. VYNE Therapeutics has a 1 year low of $1.57 and a 1 year high of $4.30.

Institutional Investors Weigh In On VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest holding. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is currently owned by institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.